Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration


News provided by

Maypharm

30 Dec, 2024, 05:00 GMT

Share this article

Share toX

Share this article

Share toX

  • Introducing Hyaluronic Acid, Exosomes, and PDRN

SEOUL, South Korea, Dec. 30, 2024 /PRNewswire/ -- Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a groundbreaking hybrid mesotherapy filler designed to redefine skin hydration and revitalization.

Maypharm Co., Ltd. is set to revolutionize the aesthetic industry with the introduction of Hyalmass Aqua-Exosome. This cutting-edge hybrid filler combines the power of hyaluronic acid, exosomes, and PDRN to maximize skin hydration, elasticity, and regeneration.

Continue Reading
This image opens in the lightbox
Hyalmass Aqua-Exosome
This image opens in the lightbox
Hyalmass Aqua-Exosome
This image opens in the lightbox
Beauty Factory

Hyalmass Aqua-Exosome is a breakthrough in aesthetic innovation, offering unmatched benefits for skin health and rejuvenation. Unlike traditional hydration fillers that focus solely on moisture, Hyalmass Aqua-Exosome elevates skin health standards by leveraging the regenerative potential of exosomes and PDRN.

"At Maypharm, we are committed to pushing the boundaries of aesthetic technology to deliver transformative results for our customers," says KWON JONGWOOK, CEO of Maypharm Co., Ltd. "With Hyalmass Aqua-Exosome, we aim to provide a comprehensive solution that not only hydrates the skin but also promotes long-term elasticity and regeneration."

Key Features of Hyalmass Aqua-Exosome:

  1. Advanced Formulation: Hyalmass Aqua-Exosome contains a unique blend of hyaluronic acid, exosomes derived from human stem cell conditioned media and plant sources, and PDRN (polydeoxyribonucleotide). This innovative combination maximizes skin regeneration and elasticity, resulting in visibly smoother and more radiant skin.
  2. Prefilled Syringes: Hyalmass Aqua-Exosome comes conveniently packaged in prefilled syringes, ensuring optimal hygiene and safety for both patients and practitioners.
  3. Long-lasting Efficacy: Utilizing high-purity, high-molecular-weight raw materials, Hyalmass Aqua-Exosome delivers long-lasting benefits to the skin, enhancing its viscoelasticity and overall vitality.
  4. Stimulates Fibroblasts: The primary ingredient in Hyalmass Aqua-Exosome stimulates fibroblasts to promote collagen and elastin production, leading to improved skin elasticity, anti-aging effects, and enhanced skin regeneration.

In comparison to traditional hydration fillers, Hyalmass Aqua-Exosome emerges as the superior choice. While conventional hydration fillers deliver quick moisture, their benefits are often limited to hydration alone, offering minimal regenerative effects. In contrast, Hyalmass Aqua-Exosome not only provides immediate hydration with hyaluronic acid but also promotes long-term skin elasticity and regeneration through the inclusion of exosomes and PDRN. This innovative formulation leads to a significant overall improvement in skin condition, positioning Hyalmass Aqua-Exosome as a revolutionary advancement in aesthetics.

With the launch of Hyalmass Aqua-Exosome, Maypharm Co., Ltd. continues its commitment to innovation, excellence, and customer satisfaction in the field of cosmetic medicine and dermo-cosmetic products. Experience the future of medical and aesthetics with Hyalmass Aqua-Exosome and unlock the secret to radiant, youthful-looking skin.

Partnership with Beauty Factory:

The production of Hyalmass Aqua-Exosome is supported by Beauty Factory, a leading Korean medical aesthetics manufacturer renowned for its commitment to innovation and quality. While Maypharm is responsible for the global distribution and commercialization of Hyalmass Aqua-Exosome, Beauty Factory's advanced manufacturing capabilities ensure that this product meets the highest industry standards.

Beauty Factory operates state-of-the-art facilities that comply with international Good Manufacturing Practice (GMP) guidelines. With their proprietary HALO manufacturing technology, developed through partnerships with prestigious academic institutions like KINS Lab at Seoul National University and the Biomaterial Synthesis Lab at Sookmyung University, Beauty Factory maintains its leadership in medical aesthetics. Their collaborations with renowned global R&D partners in Poland and Germany further enhance the scientific and technological advancements that support the creation of Hyalmass Aqua-Exosome.

Quality Control at Beauty Factory:

Beauty Factory's rigorous quality control process ensures that every product, including Hyalmass Aqua-Exosome, meets the highest standards for safety and efficacy. With a 7-step quality control (QC) system in place, Beauty Factory guarantees that all products undergo meticulous testing to ensure consistent and reliable performance across all applications.

Maypharm, in collaboration with Beauty Factory, is excited to introduce a product that combines cutting-edge technology and advanced formulation to not only provide immediate skin hydration but also support long-term skin health and rejuvenation, establishing a new standard in the aesthetic industry.

For more information about Hyalmass Aqua-Exosome and other products from Maypharm Co., Ltd., please visit www.maypharm.net or contact sales@maypharm.co.kr.

Photo - https://mma.prnewswire.com/media/2587984/Hyalmass_Aqua_Exosome.jpg
Photo - https://mma.prnewswire.com/media/2587985/Hyalmass_Aqua_Exosome_1.jpg
Photo - https://mma.prnewswire.com/media/2587986/Beauty_Factory.jpg

Modal title

Also from this source

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world's first recombinant human collagen filler, marking a significant breakthrough in skin...

More Releases From This Source

Explore

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Retail

Retail

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.